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ABSTRACT 
In the remitted phase of bipolar I disorder, sexual dysfunction is commonly due to drugs used in the treatment rather than the disease
itself. There are very few studies, especially in the Indian population, addressing the frequency of sexual dysfunction due to
antipsychotics in bipolar I disorder. Hence this study was done to determine the sexual dysfunction due to antipsychotics and to
compare the same among typical and atypical antipsychotics. A cross sectional study with 108 male patients of remitted bipolar I
disorder (DSM-IV), chosen by purposive sampling technique was done. Psychopathology was assessed using the Brief Psychiatric
Rating Scale, Structured Interview Guide for the Hamilton Depression Rating Scale and Young Mania Rating Scale. Sexual side effects
due to antipsychotics were assessed using the Udvalg for Kliniske Undersogelser (UKU) side effect rating scale. The total sample size
was divided into two groups of those on typical antipsychotics (n = 53) and atypical antipsychotics (n = 55). The two groups were
compared for sexual dysfunction using Chi-square test. Results showed dysfunction in at least one phase of the sexual response cycle,
comprising of desire, arousal and orgasm, was present in 66% of the sample population. Erectile dysfunction was present in 42% of the
sample population and it was the most common type of sexual dysfunction reported. It was also significantly different across the two
groups (p = 0.025). There was no significant difference in other aspects of sexual dysfunction across the two groups. In conclusion
patients of Bipolar I disorder experience sexual side effects of antipsychotics frequently. Erectile dysfunction is the most common
sexual dysfunction among men and this is significantly higher with typical than atypical antipsychotics.
Introduction
Sexual function is our physiologic capacity for desire, arousal
and orgasm. In women, low sexual desire is the most
common problem and for men, it is erectile dysfunction
(Bancroft, 1989). Sexual dysfunction can result from a wide
variety of psychological and physical causes and a variety
of drugs including antipsychotics.
Antipsychotics being the mainstay in the treatment of
schizophrenia, sexual dysfunction due to antipsychotics has
been currently studied extensively in this patient group
(Burke et al., 1994; Aizenberg et al., 1995; Smith et al.,
2002; MacDonald et al., 2003). The primary underlying
mechanism is likely to be the direct dopamine antagonist
effect (Gitlin, 1994). Serotonin mechanisms are also
important in antipsychotic treatment and its relationship to
sexual dysfunction. (Meston & Frohlich, 2000). Further,
Hummer et al. (1999), Wirshing et al. (2002), Bobes et al.
(2003) and Aizenburg et al. (2001) have compared the
sexual dysfunction due to typical and atypical antipsychotics
in the patients of schizophrenia. Except for the latter, the
other studies have not found overall sexual dysfunction to
be significantly different across the two groups.
Even in bipolar I disorder, the major impact on impaired
sexual functioning is due to antipsychotics and
antidepressants. There are abundant studies of sexual
dysfunction due to antidepressants, but the long term use
of antipsychotics in bipolar I disorder itself being less studied
(Taylor et al., 2003), research on sexual dysfunction due to
antipsychotics in this patient population is meager, especially
so in the Indian population. Some studies selecting mixed
patient population (affective and non-affective psychosis)
have revealed that in affective psychosis, sexual dysfunction
is less than that of non-affective psychosis (Lingjaerde et
al., 1987; Kockott & Pfeiffer, 1996; Raja & Azzoni, 2003).
So this study was aimed at studying the frequency of sexual
dysfunction due to typical and atypical antipsychotics and
to compare the two  in remitted bipolar I disorder.
METHOD
Study design and sample
The index study was conducted at the Central Institute of
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Psychiatry, Ranchi. It was a cross- sectional hospital based
study. The subjects were recruited for the study by the
purposive sampling technique. The study sample consisted
of 108 male patients of remitted bipolar I disorder, meeting
the DSM- IV criteria, aged  between 18-50 years, having
sexual activity for the past one month, on regular treatment
with an antipsychotic (typical or atypical) for at least six
weeks and giving informed consent. They were divided
into two groups-  group I consisted of 53 patients on typical
antipsychotics and group II of 55 patients, on atypical
antipsychotics. Patients with co-morbid medical disorder
(diabetes mellitus, hypertension etc and on treatment for
the same) or organic diseases (urological conditions,
lymphatic diseases of the penis etc) known to cause sexual
dysfunction, having primary sexual dysfunction, having
concurrent psychiatric diagnosis known to affect sexual
functioning (alcohol and other substance dependence,
schizoaffective disorder etc) and symptomatic patients were
excluded from the study.
Assessments
After collecting the required socio-demographic and clinical
data from the patients, they were rated on Young Mania
Rating Scale (YMRS) (Young et al., 1978), Structured
Interview Guide for the Hamilton Depression rating scale
(SIGH-D) (Janet and Williams, 1988) and Brief Psychiatric
Rating Scale (BPRS) (Overall and Gorham, 1988) to
determine the remission status. Patients with SIGH - D
score more than seven and/or YMRS score more than four
and having active psychopathology as assessed by BPRS
were not included in the study.
Subsequently they were rated on the Udvalg for Kliniske
Undersogelser (UKU) side effect rating scale (Lingjaerde
et al., 1987) to determine the sexual dysfunction in all
spheres including desire, erection, ejaculation and orgasm.
In the UKU Scale, there are ten items  that rate the
presence and severity of reproductive and sexual side
effects, namely menorrhagia, amenorrhoea, galactorrhoea,
gynaecomastia, increased sexual desire, diminished sexual
desire, erectile dysfunction, ejaculatory dysfunction,
orgasmic dysfunction and dry vagina.  Each item is rated
on a scale of 0 to 3. For the purpose of statistical analysis,
patients with a score of one or higher on the items related
to sexual functioning of the UKU side effect rating scale
were considered. Further total scores on the four subgroups
of psychic, autonomic, neurological and other side effects
were analysed to determine the spectrum of side effects
due to antipsychotics.
Analysis
Descriptive statistics was applied to describe the frequency
of sample distribution. Mann-Whitney U test was applied
to see the group differences in socio-demographic and
clinical variables and the Chi-square test was applied to
see whether the use of concurrent medicines differed across
the two groups and to compare the sexual dysfunction across
the two groups.
RESULTS
Socio-demographic and clinical characteristics
With respect to the various socio-demographic variables
like religion, occupation, marriage etc, the two groups were
not differing significantly. Further none of the clinical
variables like age, duration of illness, number of episodes,
period of remission and duration of treatment were found
to be differing significantly across the two groups. But the
autonomic side effects were found to be significantly higher
among those on typical antipsychotics. The total scores on
the  various tools used in the study also did not differ
significantly across the two groups. The clinical variables
are represented in tables 1 and  2.
Medication used by the study groups
In group I, 26 patients were on chlorpromazine, 23 were on
haloperidol, 2 patients were on trifluoperazine and 1 patient
was on thioridazine. One patient on trifluoperazine was also
on depot fluphenazine. In group II, 48 patients were on
olanzapine, 5 patients were on risperidone and two were
on clozapine. The mean chlorpromazine equivalent of typical
and atypical antipsychotics were calculated to be 319.29 ±
231.22 mg and 277.04 ± 213.47 mg respectively. However
the chlorpromazine equivalent dose was not found to be
significantly differing across the two antipsychotic groups
(p= 0.326).
A total of 50 patients were concurrently on trihexyphenidyl
out of which 38 patients were on typical antipsychotics.
This was expected as trihexyphenidyl is often needed to
control the troublesome extrapyramidal side effects
associated with the typical antipsychotics.
Lithium was the mood stabilizer used commonly by the
patients (n = 60). Sodium valproate (n=21), carbamazepine
(n=23) and lamotrigine (n=1) were the other mood stabilizers
used. Three patients were not on any mood stabilizers and
out of the remaining 105 patients, 16 were on a combination
of two mood stabilizers. Both the groups were evenly
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Table 1:
GROUP DIFFERENCE OF CLINICAL VARIABLES
Mean rank of Sum of ranks of
Variables antipsychotic antipsychotic
groups groups z p
n1 (53) n2 (55) n1 (53) n2 (55)
Age (yrs) 57.10 51.99 3026.50 2859.50 1.070 0.396
Duration of illness (months) 53.12 55.83 2815.00 3070.50 0.880 0.653
No of episodes 54.08 54.90 2866.50 3019.50 0.868 0.890
Duration of last episode (months) 54.74 54.27 2901.00 2985.00 0.880 0.938
Remission (months) 50.85 58.02 2695.00 3191.00 0.195 0.233
Duration of treatment (months) 52.58 56.35 2786.50 3099.50 0.532 0.530
Mann Whitney - U test
p = NS
n1 = Typical antipsychotic group
n2 = Atypical antipsychotic group
Table 2:
GROUP DIFFERENCE OF TOTAL SCORES ON THE VARIOUS RATING SCALES
Mean rank of Sum of ranks of
Variables antipsychotic antipsychotic z p
groups groups
n1 (53) n2 (55) n1 (53) n2 (55)
YMRS total score 54.48 54.52 2887.50 2998.50 0.007 0.994
SIGH-D total score 57.43 51.67 3044.00 2842.00 0.970 0.332
BPRS total score 55.75 53.30 2954.50 2931.50 0.413 0.679
UKU – total psychic side effects 58.22 50.92 3085.50 2800.50 1.227 0.220
UKU – total neurologic side effects 58.25 50.89 3087.00 2799.00 1.360 0.174
UKU – total autonomic side effects 60.18 49.03 3189.50 2696.50 2.040 0.041*
UKU – total other side effects 54.87 54.15 2908.00 2978.00 0.122 0.903
UKU – total side effects score 58.51 50.64 3101.00 2785.00 1.310 0.190
Mann Whitney - U test
p * = 0.05 level of significance
** = 0.01 level of significance
n1 = Typical antipsychotic group
n2 = Atypical antipsychotic group
matched as far as the usage of all the mood stabilizers was
concerned. Chi-square test did not reveal any significant
difference in the usage of different mood stabilizer across
the two groups. This is represented in table 3.
Comparison of sexual dysfunction
The total scores in the section of sexual side effects of
UKU side effect rating scale are compared in the table 4.
Erectile dysfunction was the most commonly reported sexual
dysfunction and was seen in 41.7% of the total population.
This was significantly high among those on typical
antipsychotics (p = 0.025).
39  percent of the total population reported reduced libido,
17.6% reported ejaculatory dysfunction and 14.8% were
found to have orgasmic difficulties. Overall, 66% of the
patient population  were having at least one type of sexual
dysfunction. Apart from erectile dysfunction, there was no
significant difference across the two groups in the other
aspects of sexual dysfunction as shown in the table 5.
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DISCUSSION
Methodological considerations
The present study is a single contact hospital based study
done to test the hypothesis formulated based on available
literature and aimed at assessing the sexual dysfunction
due to antipsychotics in bipolar I disorder and comparing
the sexual dysfunction due to typical and atypical
Table 3:
MOOD STABILIZERS AND  TRIHEXYPHENIDYL ACROSS TYPICAL
(n=53) AND ATYPICAL ANTIPSYCHOTICS (n=55)
Sl. Drug Typical Atypical Total c 2 df Exact sig.
No. n (53) n (55) N (108) (2-sided)
1. Patients receiving
one or more 52 53 105 2.146 2 0.342
mood stabilizers
2. Trihexyphenidyl 38 12 50 27.009 1 0.000**
*=0.05 level of significance
**=0.01 level of significance
Table 4:
TOTAL SCORES IN THE SECTION OF SEXUAL
SIDE EFFECTS OF UKU SIDE EFFECT
RATING SCALE ACROSS THE TWO GROUPS
Scores on UKU Typical n (%) Atypical n (%)
.00 16 (30.2) 21 (38.2)
1.00 7 (13.2) 9 (16.4)
2.00 9 (17.0) 10 (18.2)
3.00 8 (15.1) 5 (9.1)
4.00 9 (17.0) 8 (14.5)
5.00 3 (5.7) 2 (3.6)
6.00 1 (1.9) -
Total 53 (100.0) 55 (100.0)
Table 5:
COMPARISON OF SEXUAL DYSFUNCTION ACROSS THE TWO GROUPS
Frequency of
Chi-square Type of sexual sexual dysfunction
value
Asymp. sig
dysfunction Typical (53) Atypical (55) df (2-sided)
n (%) n (%)
Increased Sexual Desire 0  (0) 1  (1.8) 0.973 1 0.324
Diminished Sexual Desire 19 (35.8) 23 (41.8) 0.440 3 0.932
Erectile Dysfunction 28 (52.8) 17 (30.9) 9.379 3 0.025*
Ejaculatory Dysfunction 9 (16.9) 10 (18.2) 0.065 2 0.968
Orgasmic Dysfunction 8 (15.1) 8 (14.5) 1.340 3 0.720
* = 0.05 level of significance
**= 0.01 level of significance
antipsychotics. The subjects attending the outpatient
department of C.I.P. were recruited by purposive sampling
technique. The cross sectional study design has an
advantage over the prospective studies that the problem of
attrition is nil. When compared to retrospective studies, the
data is more reliable in cross sectional studies. Similar study
design has been preferred in many other studies like Kotin
et al. (1976), Lingjaerde et al. (1987), Aizenberg et al.
(1995), Smith et al. (2002), Aizenberg et al. (2001), Bobes
et al. (2003) and  MacDonald et al. (2003).
In the present study, all remitted patients were incorporated,
as the patients account is less reliable during symptomatic
phase. Moreover, the disease itself may contribute to sexual
dysfunction in symptomatic phase. The UKU side effect
rating scale that has been used to assess the sexual
dysfunction  was designed by Lingjaerde et al. (1987)  and
used in a multicentre study with a sample size of 2391, to
assess the sexual dysfunction due to antipsychotics. This
scale alone has been used in some of the recent studies
assessing the sexual dysfunction, like Hummer et al. (1999)
and Bobes et al. (2003).
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Sample characteristics
The sample size in the present study was 108. Though some
studies like Lingjaerde et al. (1987) have assessed huge
sample population, majority of studies in this area have
similar sample size, ranging from n = 87 (Kotin et al., 1976)
to n = 188 (Kockott & Pfeiffer, 1996).
Since the majority of the sample population were young
(mean age : 30 yrs), the confounding bias of increasing age
causing more sexual dysfunction is negligible.  Larger
proportion of married study population is beneficial with
respect to more reliable assessment of sexual functioning.
This finding is supporting Aizenberg et al. (1995). Average
duration of antipsychotic treatment in this study population
was seven months. The duration of antipsychotic exposure
is an important factor in impaired sexual functioning. This
was not significantly differing across the two groups.
Discussion of frequency of sexual dysfunction due to
antipsychotics
Erection
In the present study, 45 out of 108 patients (41.7%) had
erectile problems, and  it is the most common type of sexual
dysfunction in this study. Similar results have been reported
by the earlier studies like Burke et al., 1994 and MacDonald
et al., 2003. Thus erectile dysfunction is found to be the
most common sexual dysfunction in men. However the
difference in the frequency of erectile dysfunction reported
in various studies can be attributed to the differences in the
tools used, race, study design and the psychiatric disorder
of the patient population.
Other domains of sexual dysfunction
In this study, 71 out of 108 patientscomplained of sexual
dysfunction, that amounts to a frequency of 65.7%,
supporting the other studies like MacDonald et al. (2003)
& Wirshing et al. (2002). Further,  42 out of 108 patients
i.e. 39% reported reduced desire and only one patient who
was in full remission, on 10mg of olanzapine and 100mg of
lamotrigine reported increased desire. An assessment of
changes in libido associated with psychotropic medications
can be difficult because psychiatric illnesses can significantly
affect sexual interest. The effect of antipsychotics on libido
is not as well characterized as other forms of sexual
dysfunction, in part because of the difficulty in measuring
changes in libido. However, the result of the present study
is supporting the Lingjaerde et al. (1987) which has also
reported an impaired libido of 37%. Ejaculatory dysfunction
in the present study was about 18% and 15% of the study
population reported orgasmic dysfunction, which is similar
to that reported by Lingjaerde et al. (1987), Hummer et al.
(1999) and MacDonald et al. (2003).
Comparing sexual dysfunction due to typical and
atypical antipsychotics
There was a significant difference in erectile problems
between the typical and atypical antipsychotic groups ,
though there was no statistical significance in desire,
ejaculation/orgasm and overall sexual dysfunction scores.
Atypical antipsychotics were found to be relatively safer
with respect to erectile dysfunction. So this study infers
that frequency of antipsychotic induced sexual side effects
are very high in bipolar I disorder.  Significant difference in
the area of erectile dysfunction between typical and atypical
antipsychotics in the present study is supporting Aizenberg
et al. (2001) and Wirshing et al. (2002), carried out in the
schizophrenic patient population. Further, in Hammer et al.
(1999), Bobes et al. (2003), MacDonald et al. (2003) and
Wirshing et al. (2002) all of which were again on
schizophrenic population, the overall sexual dysfunction has
been found to be not significantly different across the typical
and atypical antipsychotics.
Serotonergic mechanisms are found to be as important as
dopaminergic mechanisms in sexual functioning. While
typical antipsychotics block D2 receptors and thereby
stimulate increased prolactin secretion causing sexual
dysfunction, atypical antipsychotics being serotonin-
dopamine antagonists, induce their sexual side effects
through serotonin mechanisms. This can explain the sexual
dysfunction not being significantly different across the two
groups in various studies.
Mood stabilizers and sexual dysfunction:
In the present study, 105 out of 108 patients were on mood
stabilizers. Lithium was the most commonly used mood
stabilizer. Lithium has been studied for sexual dysfunction
by Kristensen and Jogrensen (1987), Ghadirian et al, (1992)
and Aizenberg et al, (1996) in bipolar affective disorder.
Studies on lithium concluded that occasionally these patients
complain of impaired libido and arousal, but this has not
caused distress to them and has not led to treatment non-
compliance. Some patients also had spontaneous recovery
while on treatment itself. Further, Lingjaerde et al, (1987)
inferred that sexual dysfunction is about 10% less frequent
among those on lithium along with an antipsychotic as
compared to those on antipsychotic alone. However, in the
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present study almost all patients were on a combination of
antipsychotic and mood stabilizer. Hence such a comparison
could not be made. Regarding valproate, there are
occasional case reports of reduced libido and arousal in
patients of bipolar disorder, but no placebo control studies.
Further carbamazepine has been found to reduce the free
serum testosterone level in the patients of epilepsy and
thereby contributing to impaired libido in some cases. But it
also has the property of microsomal enzyme induction,
thereby reducing the effective plasma concentration of the
drugs used concurrently (eg. haloperidol) and reducing their
efficacy. This may indirectly ameliorate the sexual side
effects of those drugs. However, the role of mood stabilizers
in sexual functioning  remain inconclusive.
Clinical implications
1. Sexual dysfunction is frequent among the patients of
bipolar I disorder who are receiving antipsychotics.
2. Erectile dysfunction is the most common type of sexual
dysfunction among men and this is higher with typical
antipsychotics than atypical antipsychotics.
3. Routine enquiry during clinical follow-up interviews
regarding sexual dysfunction is essential with respect
to drug compliance and disease prognosis.
Limitations
1. Gender specific results could not be generalized in this
study as it included only male patients in the sample
population.
2. Including a third group of unmedicated patients or those
on only mood stabilizer into the study could have provided
more reliable results.
3. Some of the individual antipsychotic drugs are not
represented adequately because of the relatively small
sample size.
4. We did not incorporate the procedures like penile
plethysmography and biological markers like serum
prolactin level.
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